For the benefit of patients
We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.
We are committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).
Annual Report 2018
For the benefit of patients around the world, we are continuing to establish Cresemba and Zevtera as truly global brands. In addition, by strengthening our pre-clinical and clinical oncology pipeline, we aim to become a leading provider of innovative cancer therapies in the future.
Facts & Figures
- 225 employees from 14 countries
- Headquartered in Basel, Switzerland
- Focus on oncology and anti-infectives
- Two products on the market
- Commercialization partnerships for > 100 countries